Navigation Links
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
Date:4/15/2009

s for this orally-active tubulin and topoisomerase II inhibitor compound, in patients with advanced solid tumors and lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. The poster will be presented on Wednesday, April 22, 2009, between 8 a.m. and 12 p.m. (MT) during the Experimental and Molecular Therapeutics 42 session in Hall B-F, Poster Section 37.

Copies of the abstracts that served for these posters are currently available and can be viewed on-line through the AACR 2009 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BD007B270%2DE8F6%2D492D%2D803B%2D7582CE7A0988%7D

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's qu
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... its Board of Directors.  Mr. Voyticky is currently President ... an oil and gas exploration company, and has more ... merger and acquisition consulting. The Genesis Biopharma Board now ...
... WOODLANDS, Texas, July 18, 2011 One of the ... to achieve Meaningful Use requirements in the coming years. ... learning more about Meaningful Use requirements and how these ... a free webinar at 1 p.m. EDT (10 a.m. ...
... 90% , Reduction in HIV ... SEEK, a privately owned biopharmaceutical company specializing,in ... of its HIV-v vaccine which demonstrates a one,log (approx ... placebo group, after just a single vaccine,injection. Gregory Stoloff, ...
Cached Biology Technology:Genesis Biopharma Names David Voyticky to Board of Directors 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:8/19/2014)... , August 19, 2014 Smart ... Digital Wallet Choices as latest developments, ad campaigns and ... (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:8/19/2014)... protect their young have bigger brains than counterparts that ... British Columbia study. , Stickleback fish are well known ... male of the species, rather than the female, cares ... females and researchers wanted to find out if the ... caregivers. , In the study, published recently in ...
(Date:8/18/2014)... major Arizona watershed may lose access to important segments ... is reduced by the effects of climate warming, new ... in the Verde River Basin, are already threatened or ... resources throughout the river and its tributary streams. The ... (Gila robusta) and Sonora sucker (Catostomus insignis). , A ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... at Johns Hopkins have discovered how to block a molecular ... oxygen during a stroke. The Hopkins study, conducted on mice, ... protein on the surface of nerve cells called the EP1 ... as ONO-8713, turns it off. , The finding ...
... garden compost to forest greenery, the mold Aspergillus fumigatus ... its impact. The most common mold causing infection, A. ... among people with weakened immune systems. , Now, in ... scientists at The Institute for Genomic Research (TIGR) and their ...
... Chinese men are selectively switching from traditional Chinese ... but sticking with tradition for ailments such as ... published in Environmental Conservation. , The finding supports ... at the advent of Viagra's commercial release in ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Breaking the mold: Research teams sequence three fungus genomes 2Viagra's hidden help for wildlife 2
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
Biology Products: